SCN5A Gene

SCN5A Gene

Overview

SCN5A Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SCN5A Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SCN5A</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SCN5A</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SCN5A" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">148 edges</a></td>
</tr>
</table>

SCN5A encodes Nav1.5, the primary voltage-gated sodium channel (NaV1.5) in the cardiac conduction system["@catterall2012"][@rook2012]. While primarily studied for its cardiac functions, SCN5A variants can influence neurological outcomes through cardiac comorbidities, autonomic dysfunction, and potential direct effects on neuronal excitability. In neurodegenerative disease contexts, SCN5A is most relevant as a systems-level modifier affecting cardiac-autonomic vulnerability, medication safety, and overall disease burden in patients with [Parkinson's disease](/diseases/parkinsons-disease), [multiple system atrophy](/diseases/multiple-system-atrophy), and [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies)[@goldstein2021][@kaufmann2022].

Gene and Protein Structure

Gene Organization

The SCN5A gene is located on chromosome 3p21 and consists of 28 exons spanning approximately 80 kb of genomic DNA[@catterall2012]. It encodes a large transmembrane protein of 2016 amino acids forming the alpha subunit of the cardiac sodium channel.

Protein Architecture

Nav1.5 contains several critical structural components[@catterall2012][@rook2012]:

• Four homologous domains (I-IV): Each containing six transmembrane segments (S1-S6)
• Voltage sensor domain (VSD): Segments S1-S4 respond to membrane depolarization
• Pore domain: Segments S5-S6 form the ion selectivity filter
• N-terminal domain: Contains inactivation gate and interaction sites
• C-terminal domain: Modulates channel gating and protein interactions

Isoforms and Variants

Multiple splice variants exist:

• Canonical isoform: Full-length Nav1.5 (2016 aa)
• Alternative splicing: Produces functionally distinct isoforms
• Pathogenic variants: Over 300 disease-causing mutations identified

Cardiac Electrophysiology

Action Potential Generation

Nav1.5 mediates the rapid inward sodium current (INa) responsible for phase 0 depolarization in cardiac myocytes[@catterall2012][@rook2012]:

• Peak INa: Initiates rapid depolarization
• Late INa: Small persistent current affecting repolarization
• Window current: Sustained current within specific voltage range

Conduction System Function

Nav1.5 is essential for cardiac conduction[@rook2012]:

• Sinoatrial node: Sets pacemaker automaticity
• Atrioventricular node: Conducts impulses to ventricles
• His-Purkinje system: Enables rapid ventricular activation

Channel Gating

Multiple regulatory mechanisms control Nav1.5 function:

• Voltage-dependent activation: Rapid opening upon depolarization
• Fast inactivation: N-type inactivation mediated by IFM motif
• Slow inactivation: C-type affecting sustained currents
• Modulation: By intracellular ions, kinases, and auxiliary subunits

Clinical Genetics

Disease Associations

SCN5A variants cause multiple cardiac channelopathies[@catterall2012][@rook2012][@goldstein2021]:

• Brugada syndrome: Loss-of-function variants causing ST-segment elevation
• Long QT syndrome type 3: Gain-of-function variants prolonging QT interval
• Cardiac conduction disease: Progressive loss of conduction velocity
• Atrial fibrillation: Multiple susceptibility variants
• Dilated cardiomyopathy: Some loss-of-function mutations

Genotype-Phenotype Correlations

Variant location predicts phenotype[@rook2012][@goldstein2021]:

• Domain I variants: Often cause Brugada syndrome
• Domain II-III variants: Mixed phenotypes
• Domain IV variants: Often cause LQT3
• C-terminal variants: Conduction disease, cardiomyopathy

Neurological Disease Comorbidities

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), SCN5A is relevant through[@goldstein2021][@kaufmann2022]:

Autonomic Dysfunction

• PD often causes cardiac autonomic failure
• SCN5A variants may compound conduction abnormalities
• Increased risk of orthostatic hypotension

• Many PD medications affect cardiac conduction
• QT prolongation with some dopamine agonists
• SCN5A variants increase arrhythmia risk with medication

• Higher burden of cardiac disease in PD patients
• Lewy body pathology can affect cardiac [neurons](/entities/neurons)
• SCN5A screening relevant for risk stratification

Multiple System Atrophy

In [MSA](/diseases/multiple-system-atrophy)[@kaufmann2022]:

• Autonomic failure is a hallmark feature
• SCN5A cardiac conduction abnormalities may worsen outcomes
• Sudden cardiac death risk elevated

Dementia with Lewy Bodies

In [DLB](/diseases/dementia-with-lewy-bodies):

• Autonomic dysfunction common
• Cardiac denervation similar to PD
• SCN5A as modifier of cardiac risk

Therapeutic Implications

Medication Management

SCN5A status affects drug therapy[@catterall2012][@goldstein2021]:

Anti-Parkinsonian Drugs

• Dopamine agonists: Some prolong QT
• MAO-B inhibitors: Generally safe
• Levodopa: Monitor cardiac function

• Class I sodium channel blockers: Contraindicated in Brugada
• Beta-blockers: First-line for many arrhythmias
• Ivabradine: Heart rate reduction only

• Many non-cardiac drugs affect sodium channels
• Drug-induced arrhythmias in susceptible individuals
• Pre-treatment ECG screening recommended

Device Therapy

Pacemaker/defibrillator considerations[@rook2012]:

• High-risk patients may need permanent pacing
• ICD consideration for sudden death prevention
• Device interactions with neurological conditions

Future Therapeutics

Emerging approaches include[@catterall2012]:

• Gene therapy: AAV-mediated SCN5A delivery
• Channel modulators: isoform-selective compounds
• Precision medicine: Variant-specific treatments

Interaction with Neurodegenerative Pathways

Calcium Dysregulation

While primarily a sodium channel, SCN5A intersects with calcium signaling[@goldstein2021]:

• Sodium-calcium exchanger (NCX) coupling
• Secondary calcium overload in failure
• Excitotoxicity mechanisms

Oxidative Stress

Cardiac tissue in neurodegeneration shows oxidative changes:

• Mitochondrial dysfunction affects sodium channel function
• [ROS](/entities/reactive-oxygen-species) modification of channel proteins
• Antioxidant therapy may protect function

Protein Aggregation

Emerging links between aggregation and conduction[@kaufmann2022]:

• [α-Synuclein](/proteins/alpha-synuclein) affects cardiac neurons](/proteins)
• [Tau](/proteins/tau) pathology in cardiac tissue
• Possible direct effects on ion channels

Research Methods

Electrophysiology

Key experimental approaches[@catterall2012][@rook2012]:

• Patch clamp: Whole-cell and single-channel recordings
• Action potential mapping: Optical imaging
• ECG analysis: Surface and invasive

Genetics

• Sanger sequencing: Variant confirmation
• Next-generation sequencing: Panel testing
• Functional assays: Patch clamp of variant channels

Model Systems

Research models include:

• Cell lines: Cardiomyocytes, neurons
• Animal models: Transgenic mice, zebrafish
• Patient-derived: iPSC-cardiomyocytes

Epidemiology

Population Genetics

• Carrier frequency: ~0.1% for pathogenic variants
• Founder mutations: Specific populations (e.g., South Asian)
• Variant interpretation: Many variants of uncertain significance

Disease Burden

Cardiac disease in neurodegeneration[@goldstein2021][@kaufmann2022]:

• 50-80% of PD patients have autonomic dysfunction
• Sudden cardiac death risk elevated
• Cardiac comorbidities increase mortality

Clinical Management

Screening Recommendations

For neurodegenerative patients[@goldstein2021][@kaufmann2022]:

• Baseline ECG: Before starting conduction-affecting medications
• Periodic monitoring: For high-risk patients
• Family history: Assess inherited arrhythmia syndromes

Multidisciplinary Care

Optimal management requires coordination:

• Cardiology: Electrophysiology input
• Neurology: Neurodegeneration management
• Primary care: Overall coordination

See Also

• [Parkinson's disease](/diseases/parkinsons-disease)](/proteins/parkin)
• [multiple system atrophy](/diseases/multiple-system-atrophy)
• [dementia with Lewy bodies](/diseases/dementia-with-lewy-bodies)](/diseases/dementia-with-lewy-bodies)
• [MSA](/diseases/multiple-system-atrophy)
• [DLB](/diseases/dementia-with-lewy-bodies)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SCN5A Gene discovered through SciDEX knowledge graph analysis:

Expression Profile

Sources: [GTEx Portal v10](https://gtexportal.org/home/gene/scn5a) | [Allen Brain Atlas](https://www.brain-map.org/)

GTEx Tissue Expression (median TPM)

| Rank | Tissue | Median TPM |
|------|--------|------------|
| 1 | Heart Atrial Appendage | 36.13 |
| 2 | Heart Left Ventricle | 35.11 |
| 3 | Cervix Ectocervix | 5.35 |
| 4 | Cervix Endocervix | 4.12 |
| 5 | Nerve Tibial | 2.92 |
| 6 | Artery Aorta | 1.86 |
| 7 | Vagina | 1.83 |
| 8 | Ovary | 1.53 |
| 9 | Prostate | 0.99 |
| 10 | Uterus | 0.87 |
| 11 | Bladder | 0.86 |
| 12 | Artery Tibial | 0.81 |
| 13 | Colon Sigmoid | 0.76 |
| 14 | Brain Hypothalamus | 0.76 |
| 15 | Testis | 0.74 |

Brain-Region Expression:

| Region | Median TPM |
|--------|------------|
| Brain Hypothalamus | 0.76 |
| Brain Cortex | 0.64 |
| Brain Frontal Cortex BA9 | 0.50 |